Br J Radiol. 2025 Oct 1;98(1174):1606-1614. doi: 10.1093/bjr/tqaf014. ABSTRACT OBJECTIVES: To evaluate F-DCFPyL PET/MRI whole-gland-derived radiomics for detecting clinically significant (cs) prostate cancer (PCa) within the prostate gland and predicting extra-prostatic metastasis (N and M staging). METHODS: In this single-centre,…
Prostate-specific antigen density does not predict metastatic disease on PSMA-PET in high-risk prostate cancer patients with negative conventional imaging
Can Urol Assoc J. 2025 Sep;19(9):E307-E311. doi: 10.5489/cuaj.9113. ABSTRACT INTRODUCTION: The ability of prostate-specific antigen density (PSAD) to predict metastatic disease on prostate-specific membrane antigen-positron emission tomography (PSMA-PET) at initial staging in high-risk prostate cancer (PCa) for men with negative…
Targeted Radionuclide Therapy Using a Lutetium-177 Labeled Human Anti-CD133 Antibody
Mol Imaging Biol. 2025 Aug;27(4):606-616. doi: 10.1007/s11307-025-02013-4. Epub 2025 May 22. ABSTRACT PURPOSE: Targeted radionuclide therapy against cancer stem cell-specific markers, such as CD133, constitutes a promising strategy to eliminate resilient cancer stem cells for improved outcomes in refractory tumors.…
PSMA PET-detected mesorectal nodal metastasis: treatment outcomes and clinical implications
World J Urol. 2025 Jun 3;43(1):352. doi: 10.1007/s00345-025-05733-y. ABSTRACT PURPOSE: To evaluate the clinical significance of PSMA-PET/CT-detected mesorectal lymph node metastases in biochemically recurrent prostate cancer patients. METHODS: This is a retrospective analysis of biochemically recurrent prostate cancer patients (post-radical…
Convection-enhanced delivery of [177Lu]Lu-labeled gold nanoparticles combined with anti-PD1 checkpoint immunotherapy improves the survival of immunocompetent C57BL/6J mice with orthotopic GL261 murine glioma tumors
Nucl Med Biol. 2025 Jan-Feb;140-141:108970. doi: 10.1016/j.nucmedbio.2024.108970. Epub 2024 Nov 9. ABSTRACT INTRODUCTION: Our objective was to study convection enhanced delivery (CED) of 177Lu-labeled metal chelating polymer (MCP) conjugated to gold nanoparticles (Lu-MCP-AuNP) alone or combined with anti-PD1 immune checkpoint…
18 F-DCFPyL in the Detection of Prostate Cancer Spread to the Lumbosacral Plexus
Clin Nucl Med. 2025 Apr 1;50(4):e232-e233. doi: 10.1097/RLU.0000000000005472. Epub 2024 Dec 13. ABSTRACT In most cases, prostate cancer spreads locally to the seminal vesicles, via lymphatics to pelvic and abdominal lymph nodes, and hematogenously to the bones. Direct invasion along…
Association of Free-to-Total PSA Ratio and (18)F-DCFPyL Prostate-Specific Membrane Antigen PET/CT Findings in Patients with Biochemical Recurrence After Radical Prostatectomy: A Prospective Single-Center Study
J Nucl Med. 2024 Nov 1;65(11):1731-1739. doi: 10.2967/jnumed.124.267877. ABSTRACT In Canada and across the globe, access to PSMA PET/CT is limited and expensive. For patients with biochemical recurrence (BCR) after treatment for prostate cancer, novel strategies are needed to better…
Pre-treatment 68 Ga-PSMA-11 PET/CT Prognostic Value in Predicting Response to 177Lu-PSMA-I&T Therapy and Patient Survival
Mol Imaging Biol. 2024 Apr;26(2):360-369. doi: 10.1007/s11307-024-01900-6. Epub 2024 Feb 15. ABSTRACT PURPOSE: To assess the prognostic value of pre-treatment Ga-PSMA-11 PET/CT and other baseline clinical characteristics in predicting prostate cancer (PCa) patients response to Lu-PSMA (PSMA-I&T), as well as…
Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases Through (18)F-DCFPyL-Prostate-Specific Membrane Antigen-Positron Emission Tomography/CT Scans in Pretreatment Prostate Cancer Patients
J Urol. 2024 Apr;211(4):586-593. doi: 10.1097/JU.0000000000003850. Epub 2024 Feb 1. ABSTRACT PURPOSE: Intraductal prostate cancer (IDC) is linked to unfavorable oncologic outcomes, marked by distinctive cellular intrinsic pathway changes and intricate immunosuppressive microenvironments that could impact the way cancer spreads.…
Lymphotropic Pattern of Prostate-specific Membrane Antigen-detected Metastases Among Biochemically Recurrent Radical Prostatectomy Patients with Cribriform Disease
Eur Urol Focus. 2023 Nov;9(6):1016-1023. doi: 10.1016/j.euf.2023.05.005. Epub 2023 May 31. ABSTRACT BACKGROUND: Cribriform morphology portends worse oncologic outcomes, and has unique cellular intrinsic pathway alterations and tumor microenvironments that may impact metastatic spread patterns. OBJECTIVE: To determine whether the…